Rohin K Patel, an analyst from J.P. Morgan, maintained the Buy rating on NeuroPace. The associated price target is $20.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rohin K Patel has given his Buy rating due to a combination of factors tied to both near‑term execution and long‑term potential. NeuroPace modestly surpassed first‑quarter revenue expectations and raised full‑year guidance by more than the size of the beat, while still embedding conservative assumptions that exclude any meaningful upside from the pending IGE label expansion.
Patel also highlights NeuroPace’s differentiated RNS platform, which addresses a substantial unmet need in drug‑resistant epilepsy with a closed‑loop neuromodulation system that can detect and respond to seizures in real time. Combined with a robust iEEG data asset, multiple future indication and partnership catalysts, and a projected ~20% revenue CAGR through 2029, he views the current valuation and $20 price target (about 5x 2027 revenue) as attractive versus high‑growth med‑tech peers, justifying the Buy recommendation.